Drawing for ONCOSIGNATURE

USPTO serial 98115652

ONCOSIGNATURE

Reviewed by CopyMark Law Group

Status 730Notice of Allowance
Filing date
Status date
Registration date
—
Examiner
SMITH, REBECCA A
Law office
INTENT TO USE SECTION

What this means

The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.

Status 730: Status 730 means you filed the first six-month extension to delay filing a Statement of Use after a Notice of Allowance. You must file a Statement of Use or another extension before the new deadline.

Need help with ONCOSIGNATURE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $648*

Plus Government fees of $300

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

SARA M. BAUER

SARA M. BAUER WOMBLE BOND DICKINSON (US) LLP470 ATLANTIC AVENUE, SUITE 600INDEPENDENCE WHARFBOSTON, MA 02110

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical and medical preparations for the prediction of drug treatment efficacy; pharmaceutical and medical preparations for prognosis related to cancer; diagnostic kits consisting primarily of monoclonal antibodies for use in disease testing, specifically in oncology and premalignant disorders and benign tumors; reagents for medical use, namely, for medical diagnosis, drug-tailored efficacy predication and analysis; clinical medical reagents; diagnostic preparations for medical and veterinary purposes; diagnostic test materials for medical use in the field of oncology in the form of a clinical biomarker signature assay on biopsy or other patient sample material for measuring biomarkers reflective of disease-driving processes that the drug inhibits or does not inhibit to predict treatment efficacy within oncology; diagnostic preparations for medical use; diagnostic biomarker reagents for medical purposes; companion diagnostic biomarker reagents for medical purposesACTIVE—
044Medical services; medical testing for diagnosis or treatment purposes; medical diagnostic testing, monitoring, and reporting services; providing medical information, medical consultancy and medical advisory services; individual medical counseling services provided to patients; providing a website featuring medical information in the fields of oncology and precision medicine; providing medical information to medical professionals in the form of reports in the fields of oncology and precision medicineACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 17, 2026EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Sep 14, 2026EX1GSOU EXTENSION 1 GRANTED—
Sep 14, 2026EXT1SOU EXTENSION 1 FILED—
Sep 14, 2026EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Mar 31, 2026NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Mar 28, 2025EPPATEAS POST PUBLICATION AMENDMENT RECEIVED—
Mar 19, 2025TMBNTTAB RELEASE CASE TO TRADEMARKS—
Mar 19, 2025OP.TOPPOSITION TERMINATED NO. 999999—
Mar 19, 2025OP.DOPPOSITION DISMISSED NO. 999999—
Nov 3, 2024ETOPEXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED—
Nov 1, 2024OP.IOPPOSITION INSTITUTED NO. 999999—
Jun 5, 2024ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
May 7, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 7, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 17, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Apr 4, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Apr 4, 2024DOCKASSIGNED TO EXAMINER—
Oct 26, 2023TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Oct 26, 2023ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 26, 2023REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Oct 26, 2023CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Oct 26, 2023COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Sep 1, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 7, 2023NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance